ALTH

(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.(BAY) Bayer raised guidance on Schering...
Allos Therapeutics, Inc. (ALTH-NASDAQ) is indicated down almost 20% in thin pre-market trading after it announced that top line results from ENRICH, the Company’s pivotal Phase III study of...